TFX Similar Chart Price Prediction
The price of TFX is predicted to go up -0.16%, based on the high correlation periods with UNF. The similarity of these two price pattern on the periods is 92.74%.
TFX
UNF
Down: -0.16%Similarity: 92.74%
TFX Revenue Forecast
TFX EPS Forecast
TFX FAQs
What is bull’s view on TFX?
What is bear's view on TFX?
What is TFX revenue forecast for next quarter？
What is TFX eps forecast for next quarter？
TFX VS S&P500
UroLift provides a meaningful clinical benefit in an area of unmet needs. Together with Barrigel, Telelfex has a decent chance of building a strong business in interventional urology.
Teleflex's core businesses have an attractive, consistent growth profile, and successful integration of acquisitions could cement stable growth and positive returns for shareholders.
The firm's margins should meaningfully improve over time, with higher-margin UroLift 2 providing a near-term margin boost. Restructuring will provide an additional margin lift.
TFX Analyst's Forecast
Richard Newitter
Truist Securities
Hold
2024-12-18
Price Target
$227 → $200
Upside
+15.83%
Truist lowered the firm's price target on Teleflex to $200 from $227 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as "one of the better/safer houses" in healthcare given its lower "front-line" exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an "innovation segment" with sustainable above-average revenue and EPS growth, strong balance sheets, and healthy free cash flows. Truist adds that it prefers small-mid size companies over large caps as M&A may be "poised to heat up".
Richard Newitter
Truist Securities
Hold
2024-11-04
Price Target
$255 → $227
Upside
+9.49%
Anthony Petrone
Mizuho
Hold
2024-11-01
Price Target
$275 → $250
Upside
+18.37%
